CORRELATION OF MISMATCH REPAIR DEFICIENCY WITH HISTOPATHOLOGICAL SUBTYPES AND CLINICAL OUTCOME IN ENDOMETRIAL CANCER | ||
| ALEXMED ePosters | ||
| Article 1, Volume 6, Issue 4, September 2024, Pages 83-84 | ||
| Document Type: Preliminary preprint short reports of original research | ||
| DOI: 10.21608/alexpo.2024.341753.2026 | ||
| Authors | ||
| Yousri Abdelmeguid Rostom1; Maher Soliman2; Mohammed Farouk Fathy El-Shazly3; Marwa Mohamed Abdel Aziz4; Imfurankunda Habimana Honorine* 3 | ||
| 1Department of Oncology and Nuclear Medicine, Faculty of Medicine, Alexandria University | ||
| 2Department of Clinical Oncology, Faculty of Medicine, University of Alexandria | ||
| 3Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Alexandria University | ||
| 4Department of Obstetrics and Gynecology, Faculty of Medicine, Alexandria University | ||
| Abstract | ||
| Endometrial carcinoma (EC) is the most common uterine cancer and the second most frequent gynecological malignancy in Egypt and Worldwide. With the recognition of its four molecular subtypes, EC treatment strategies have changed globally, and molecular profiling is now an essential part of clinical judgment, especially for patients with POLE and p53 mutations. Contrary, Mismatch Repair Deficiency (MMRd) being the second most common and aggressive subtype of EC due to its heterogeneity, its clinical features and oncological outcomes remain controversial worldwide. In North Africa and Africa in general not only the behavior of MMRd group is disagreeable but also we still have a crucial knowledge gap regarding EC molecular profiling which is highlighted by lack of data. Aim of the work: To correlate MMRd and clinicopathological factors in endometrial cancer (EC) and assess the impact of MMRd on oncological outcomes in EC patient. Methods: This retrospective study included 43 patients diagnosed with endometrial cancer and treated at the Alexandria Clinical Oncology Department between 2020 and 2022. MMR status was assessed using immunohistochemistry, and the results were statistically correlated with clinical presentation, tumor pathological characteristics, and patient outcomes. | ||
| Keywords | ||
| Endometrial carcinoma; MMRd; p53 | ||
|
Supplementary Files
|
||
|
Statistics Article View: 6 |
||
